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Abstract
The age-standardised incidence of cervical cancer in Europe varies widely by country
(between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vac-
cine coverage is low in countries with the highest incidence and screening perfor-
mance is heterogeneous among European countries. A broad group of delegates of
scientific professional societies and cancer organisations endorse the principles of the
WHO call to eliminate cervical cancer as a public health problem, also in Europe. All
European nations should, by 2030, reach at least 90% HPV vaccine coverage among
girls by the age of 15 years and also boys, if cost-effective; they should introduce
organised population-based HPV-based screening and achieve 70% of screening
Abbreviations: ECCO, European CanCer Organisation; EFC, European Federation for Colposcopy; ESGO, European Society of Gynaecological Oncology; EU, European Union; HPV, human
papillomavirus; IARC, International Agency for Research on Cancer; WHO, World Health Organisation
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coverage in the target age group, providing also HPV testing on self-samples for non-
screened or underscreened women; and to manage 90% of screen-positive women.
To guide member states, a group of scientific professional societies and cancer orga-
nisations engage to assist in the rollout of a series of concerted evidence-based
actions. European health authorities are requested to mandate a group of experts to
develop the third edition of European Guidelines for Quality Assurance of Cervical
Cancer prevention based on integrated HPV vaccination and screening and to moni-
tor the progress towards the elimination goal. The occurrence of the COVID-19 pan-
demic, having interrupted prevention activities temporarily, should not deviate
stakeholders from this ambition. In the immediate postepidemic phase, health profes-
sionals should focus on high-risk women and adhere to cost-effective policies includ-
ing self-sampling.
K E YWORD S
cervical cancer screening, COVID-19, elimination of cervical cancer, Europe, HPV
vaccination, WHO
1 | CURRENT BURDEN OF CERVICAL
CANCER
According to the International Agency for Research on Cancer (IARC)
estimates of the cancer burden in Europe, approximately 33 000 women
were diagnosed with cervical cancer and 15 000 died from the disease in
2018.1 These estimates concern the European region as defined by the
United Nations. The incidence rates vary widely within Europe, with age-
standardised incidence rates (ASIR) ranging from less than 5/100000 in
Malta (3.5), Switzerland (3.8) and Finland (4.7) to ASIRs over 20/100000
in Latvia (25.0), Bosnia Herzegovina (23.9), Estonia (22.5), Moldova
(21.4), Serbia (20.3) and Bulgaria (20.3) (see Figure 1; Table 1).
There is a clear Western to Eastern Europe trend with ASIRs
lower than 10/100000 and age-standardised mortality rates (ASMR)
lower than 3/100000 in Northern, Southern and Western Europe,
compared with ASIR of 16/100000 and ASMR of 6/100000 in
Central-Eastern Europe. In the 28 member states of the European
Union (EU) (as defined in 2018, still including the United Kingdom),
the average age-standardised incidence and mortality rates are 10.0
and 3.1 per 100 000 women-years, respectively. For a more detailed
assessment of the burden of cervical cancer in Europe vs other conti-
nents and on the methodology of estimation, we refer to a recent
publication in Lancet Global Health1 and the description of the sources
and methods used in developing the GLOBOCAN estimates.2,3
2 | PREVENTION OF CERVICAL CANCER
Historically, screening by detection and treatment of cervical precancer
lesions identified through cytological examination of Pap smears has
resulted in a significant reduction in cervical cancer incidence and mor-
tality.4-6 The implementation of the European Guidelines for Quality
Assurance of Cervical Cancer Screening has played a pivotal role in
achieving this result.7 However, recent trend analyses indicate that
even in countries with well-organised cytology-based screening
programmes, cervical cancer incidence rates have stopped decreasing
or are even increasing.1,8-10 This phenomenon might be explained by
an increased exposure to oncogenic types of the human papillomavirus
(HPV), lower screening coverage rates, particularly among young
women, and the limitations of cytology-based screening.1
Therefore, new effective preventive tools, which have become
available in the last decade, should be implemented without delay.
Strong evidence has accumulated, indicating that primary preven-
tion by vaccination against the main carcinogenic HPV types is safe and
protects well against future HPV infection and associated anogenital
precancer in young females and males.11-15 However, current HPV
What's new?
Cervical cancer incidence, human papillomavirus (HPV) vac-
cination coverage, and screening performance vary widely
across Europe. This report addresses for the first time the
issue of how Europe should respond to the ambitious call
from the World Health Organization to reduce the incidence
of cervical cancer to less than 4/100,000/year. To meet this
target, all European countries should put in place programs
to reach 90% and 70% of HPV vaccination and screening
coverage, respectively, and manage 90% of screen-positive
women by 2030. Despite the temporary interruptions of
prevention activities caused by COVID-19, the pandemic
should not deviate stakeholders from this ambition.
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vaccine coverage estimates show very large discrepancies among coun-
tries (Table 2). The European Centre for Disease Control and Preven-
tion in its recently released guidance on HPV vaccination in EU
countries stated that a gender neutral vaccination becomes increasingly
cost-effective in the presence of persistently suboptimal coverage of
females with reducing vaccine price.16 However, in countries with HPV
vaccination coverage of 80% or higher among girls, boys are already
well protected by herd-immunity, which renders gender-neutral vacci-
nation less cost-effective. Interventions to increase vaccination cover-
age among girls where it is low might be more cost-effective than
adding vaccination of boys.17 Intervention research aiming to identify
effective strategies to increase HPV vaccination uptake and implemen-
tation of such strategies should be promoted.
Regarding secondary prevention, randomised population-based
trials have demonstrated that HPV-based screening is more per-
formant in protecting against incident cervical precancer and cancer
than cytology.18,19 In addition, screening with validated polymerase
chain reaction-based HPV assays offers the advantage that it can be
performed on a specimen collected by the woman herself. The offer
of self-sampling devices has been shown to be performant in reaching
underscreened populations.20,21 Neither the World Health Organisa-
tion (WHO) nor EU guidelines recommend screening by cotesting
with HPV and cytology.22,23
HPV infection is mainly sexually transmitted and this fact entails
sensitive and tailored communications, including appropriate health
education, to the general public as well as to individual women need-
ing counselling in order to reduce stigma, shame and worry, by taking
into account the particular social and cultural background.24,25
TABLE 1 Burden of cervical cancer in the member states of the
European Union in 2018
Member state Nb cases ASIR Nb deaths ASMR
Austria 390 5.5 163 1.7
Belgium 640 7.8 235 2.0
Bulgaria 1080 20.3 475 7.4
Croatia 266 7.9 175 3.7
Cyprus 45 5.7 18 1.5
Czech Republic 813 9.9 435 4.0
Denmark 415 10.9 131 2.0
Estonia 230 22.5 60 4.3
Finland 182 4.7 64 0.9
France 3067 6.7 1472 2.3
Germany 4608 7.5 2011 2.2
Greece 696 8.1 271 2.1
Hungary 1312 17.2 499 5.1
Ireland 340 11.0 107 2.9
Italy 3105 7.1 986 1.5
Latvia 339 25.0 134 6.5
Lithuania 431 18.9 209 7.2
Luxembourg 25 5.6 11 2.0
Malta 11 3.5 7 1.4
Poland 3220 9.4 1947 4.9
Portugal 750 8.9 340 2.8
Romania 3308 19.5 1743 8.9
Slovakia 692 16.6 281 5.7
Slovenia 110 7.1 65 2.8
Spain 1942 5.2 825 1.7
Sweden 558 9.0 222 2.0
The Netherlands 670 5.7 250 1.4
UKa 3430 8.4 1033 1.7
Whole EU 32 675 10.0 14 169 3.1
Note: Source: IARC GLOBOCAN.1
Abbreviations: ASIR, age-standardised incidence rate (cases of cervical cancer
per 100 000 women-year); ASMR, age-standardised mortality rate (deaths from
cervical cancer per 100 000 women-year), computed by using the standard
world population as reference; EU, European Union; Nb, number; UK, United
Kingdom.
aUK still was member of the EU in 2018.
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F IGURE 1 World-age-standardised rates of incidence of and
mortality from cervical cancer (/100 000 women-years), in Europe,
estimates for 2018, by country and ranked in descending order of
incidence. The red line corresponds with the WHO elimination target
(4/100000/year). Source: IARC GLOBOCAN1 [Color figure can be
viewed at wileyonlinelibrary.com]
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TABLE 2 Estimations for 2018 of the vaccine coverage in European HPV vaccination programmes (aggregated by country)
28 member countries of the EUa
Country Coverage (%) Comment
Austria – Estimate not available. No data reported
Belgium 67 Estimate extrapolated from 2016. Estimate based on weighted average of survey data from regions
(Flanders 89.5% and Wallonia-Brussels 36.1%)
Bulgaria 5
Croatia – Estimate not available. No data reported
Cyprus 64 Estimations for the Government Controlled Area
Czech Republic – Estimate not available. No data reported
Denmark 54
Estonia 44
Finland 62 Estimate based on reported coverage from the national vaccination registry
France 24
Germany 31 Data not reported. Estimate extrapolated from 2017






Luxembourg 14 Estimate extrapolated from 2015
Malta 81
Netherlands 45 Estimate based on reported coverage data for the 14th year cohort from the national vaccination registry
Portugal 80 Estimate based on reported official coverage
Romania – HPV vaccination not introduced
Slovakia – HPV vaccination not introduced
Slovenia 45
Spain 69
Sweden 75 Estimate based on reported official coverage
UKa 81
Other European countries
Country Coverage (%) Comment
Andorra – Estimate not available. No data reported
Armenia 2
Azerbaijan – Vaccine not introduced




Moldova – Vaccine not introduced
Macedonia 40
Monaco – Estimate not available. No data reported
Norway 86
Russia – Vaccine not introduced. Only in some regions
San Marino 16
Switzerland 57 Estimate based on national survey. Females who were 16 years of age at the interview.
Ukraine – Vaccine not introduced
Note: Source: ICO WHO 2018 Estimates (http://www.who.int/immunization/monitoring_surveillance/data/HPV_estimates.xls).
aIn 2018, the UK still was member of the European Union.
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3 | WHO CALL FOR THE ELIMINATION
OF CERVICAL CANCER
Recognising that cervical cancer affects many women at an age when
they have important economic and familial responsibilities, and
acknowledging its high level of preventability, has motivated the
WHO Director General to launch an appeal to all countries of the
world to eliminate this disease as a public health problem.26 It is
estimated that by vaccinating 90% of girls before they reach the age
of 15 years, by screening 70% of women at least twice in the
age-range 30 to 40 years, and by treating at least 90% of screen-
detected cervical precancer lesions, by 2030, the incidence of cervi-
cal cancer could be reduced to the level of a very rare disease (≤4
per 100 000/year) by the end of the current century.22,27 Europe as
a whole (with most countries belonging to the group with very high
human development index [HDI]) could reach this goal sooner by
2055 to 2059.27
4 | PROPOSAL FOR EUROPEAN ACTIONS
Implementation of HPV-based screening as recommended in EU
guidelines, including offering nonscreened women the choice of self-
sampling, in combination with HPV vaccination of girls, and vaccina-
tion of boys if resources permit, could achieve the WHO goal in
European countries by 2050 to 2065 depending on the current bur-
den and the chosen strategies (see red line in Figure 1).27 On the ini-
tiative of the European CanCer Organisation (ECCO) and the
European Society of Gynaecological Oncology (ESGO), a resolution
was adopted proposing as a series of goals and actions to be taken to
support the achievement of the WHO goal in Europe (https://www.
eccosummit.eu/Resolutions/HPV, see Boxes 1-5). The following orga-
nisations have endorsed this proposal for European actions: ESGO,
ECCO and European Federation for Colposcopy. Upon the initiative
of ESGO, the resolution was widened to a platform of experts and
representatives from other involved societies, and cancer institutions
and agencies.
The series of actions enumerated earlier contributing to the elimi-
nation of cervical cancer were compiled before the outbreak of the
COVID-19 pandemic. The control measures against the spread of
BOX 1 Action on HPV vaccination
• All European country cancer plans should include actions
towards achieving population-based HPV vaccination of
girls, and also vaccination of boys if cost-effective.
• Vaccination programmes against HPV infection should
be in place in all European countries.
• The target vaccination rate by 2030 in all European
countries should be at least 90% of adolescents, prefer-
entially for both genders, by the age of 15 years.
• In support of vaccination goals, global cooperation
should be fostered to resolve vaccine supply issues to
ensure sufficient vaccine doses for the vaccination
programmes of all countries.
BOX 2 Actions on HPV vaccination and screening
Guidelines on integrated HPV vaccination and cervical can-
cer screening should be regularly updated. A third edition of
evidence-based EU Guidelines for Quality Assurance in Cer-
vical Cancer Prevention should be developed, which should
include recommendations on how to screen vaccinated
populations.
BOX 3 Actions on screening and early diagnosis
• By 2030, at least 70% of women in Europe, belonging to
the target age group, should have been screened for cer-
vical cancer with a clinically validated HPV test within
the last 5 years. This coverage should be reached as part
of an organised programme. HPV screening programmes
should take into consideration innovations such as self-
sampling in order to reach women who may not partici-
pate in the regular screening programme.
• Future European guidelines should include recommenda-
tions on how to communicate the results of HPV testing
and how to counsel women and their partners to avoid
stigma and shame.
BOX 4 Actions on treatment
• Across all European countries, 90% of women with
Grade III cervical intraepithelial neoplasia should be
treated within 3 months. All women with diagnosed cer-
vical cancer should have access to appropriate oncologi-
cal services including palliative care for incurable cases.
• All European country cancer plans should include actions
towards achieving these treatment goals.
• Guidelines on HPV vaccination and cervical cancer
screening should also review the relevance of ablation
(cryotherapy, thermal ablation) as a simple, safe and effi-
cacious technique to treat cervical precancers, especially
in younger women in Europe.
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SARS-CoV-2 have interrupted the implementation of current preven-
tive programmes and delayed new activities planned in Europe and
elsewhere.28 Concerns related to cervical cancer control amidst the
COVID-19 pandemic and the period thereafter are addressed in Box 6.
BOX 5 Other actions to support the
elimination goal
HPV awareness
All European country cancer plans should include
actions towards increasing public, patient and healthcare
professional understanding and awareness of HPV. This
awareness should include the range of HPV-related cancers
and diseases, their symptoms and forms of prevention. Fur-
thermore, this communication effort should elaborate to the
public, patients and healthcare professionals on the strate-
gies being pursued to achieve the goal of cervical cancer
elimination, and the role of the public, patients and
healthcare professionals play in achieving the elimination
goal. Awareness levels of the public, patients and healthcare
professionals on HPV should be monitored and enhanced
where necessary.
Public confidence in HPV vaccination and actions against
fake news
• Health authorities and stakeholders should invest in
effective communication about the effectiveness and
safety of HPV vaccines to generate a basis for
confidence.
• Cancer societies, patient and healthcare professional
associations, and other stakeholders, should publish re-
commendations to combat the impacts on HPV vaccina-
tion uptake posed by deliberate misinformation, spread
via traditional news media (print and broadcast) or social
media, on ineffectiveness or risks associated with HPV
vaccination.
• All major social media platforms operating in Europe
should have developed and implemented strategies to
improve health literacy and reduce the spread of fake
news on vaccination.
• All national cancer plans in Europe should include actions
to combat the deterrence effects of fake news upon
HPV vaccination rates, as part of a broader campaign to
reduce the negative impact of vaccination hesitancy on
all vaccination programmes.
Improving data and monitoring
• By 2025, all European countries should have population-
based registries in place to track and report upon HPV
vaccination, HPV screening and cancer incidence and
mortality data.
• Monitoring should include reporting of harms associated
with HPV vaccinations, screening and treatment of
screen detected lesions.
• European countries should evaluate cervical cancer
screening programmes using the key performance indica-
tors harmonised through the second European Screening
Report (2017) and such evaluation reports should be
published.
Training
Health professionals (general practitioners, nurses, spe-
cialists, care givers and field workers) involved in education,
cervical cancer prevention and treatment of precancer
should be aware of the principles of cervical cancer control
and be adequately trained for their specific contributions.
Training should include objective and tailored communica-
tion of the benefits and harms from primary and secondary
prevention.
EU Cancer Mission
• The EU Cancer Mission should have clear elements
within its programme that are supportive to the WHO
global call for the elimination of cervical cancer as a pub-
lic health problem. This should include supporting
research priorities such as development and evaluation
of new vaccine and screeningtechnologies, triage of
screen-positive women using accurate markers, as well
as care and treatment techniques. Research on interven-
tions that optimise population coverage and adherence
to follow-up, risk-based management as well as imple-
mentation of science research focusing on transforming
research findings to public health benefits should also be
promoted.
• EU Cancer Mission goals, such as on prevention and treat-
ment of HPV-related disease, should be complemented by
an EU Cancer Masterplan that supports achievement in
respect to nonresearch-related matters. This might include
facilitating greater use of EU Structural Funds to achieve
EU and WHO common goals pertaining to HPV vaccina-
tion, cervical cancer screening, treatment of screen-
detected lesions, and treatment of invasive cancer, as well
as HPV awareness and education.
Monitoring of EU Member State Cancer Plans
As part of the coordination role that the EU should play
in assisting member states to combat cancer, a public moni-
toring and reporting system should be established with
respect to EU member state cancer plan items, similar to
“the State of Health in the EU.” This should include monitor-
ing of actions towards international goals on HPV-related
cancer control.
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5 | CONCLUSIONS
Previous editions of the European Guidelines for Quality Assurance in
Cervical Cancer Screening, mandated by the European Commission,
were pivotal in introducing the implementation of organised secondary
prevention of this malignancy in EU member states.23,29 Today, new
generations of vaccinated women are entering the target age group for
screening and this new situation requires updated guidance. The authors
of this article underline the need for a new third edition of EU guidelines
for integrated primary and secondary prevention of cervical cancer.
Although waiting for an official mandate from the EU Commission, a
large group of professional societies and cancer organisations are
engaged and willing to assist the WHO and European health authorities
to achieve the laudable goal of eliminating cervical cancer.
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